瑋俊生物科技(00660.HK)年度虧損約273.7萬港元 同比收窄94.9%
格隆匯5月27日丨瑋俊生物科技(00660.HK)發佈公告,截至2019年12月31日止年度,集團錄得經營業務營業額約5.79億港元,較2018年增加約20.4%;集團錄得經營業務毛利和毛利率分別約4885.7萬港元及約8.4%,較2018年分別增加約214.7%及增加5.2%;公司擁有人應占虧損約為273.7萬港元,同比收窄94.9%;基本每股虧損0.02港仙;不派末期股息。
虧損減少的主要原因是公司按公司購股權計劃授予1,595,468,537份購股權而需確認的以股份形式付款開支約3986.4萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.